Deira Trading Company

The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and diabetes drugs called GLP-1s.

Leave a Reply

Your email address will not be published. Required fields are marked *

Source: CurrencyRate